期刊
BEHAVIOURAL NEUROLOGY
卷 2015, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2015/976589
关键词
-
资金
- Centro Hospitalar do Porto's Department of Teaching, Education, and Research
- Portuguese National Funding Agency for Science, Research and Technology (FCT) [PEST-OE/SAU/UI0215/2011]
- pharmaceutical company Novartis
- Australian National Health and Medical Research Council [402764]
- Fundação para a Ciência e a Tecnologia [PEst-OE/SAU/UI0215/2011] Funding Source: FCT
Introduction. A possible association between olfactory dysfunction and Parkinson's disease (PD) severity has been a topic of contention for the past 40 years. Conflicting reports may be partially explained by procedural differences in olfactory assessment and motor symptom evaluation. Methods. One hundred and sixty-six nondemented PD patients performed the Brief-Smell Identification Test and test scores below the estimated 20th percentile as a function of sex, age, and education (i.e., 80% specificity) were considered demographically abnormal. Patients underwent motor examination after 12 h without antiparkinsonian medication. Results. Eighty-two percent of PD patients had abnormal olfaction. Abnormal performance on the Brief-Smell Identification Test was associated with higher disease severity (i.e., Hoehn and Yahr, Unified Parkinson's Disease Rating Scale-III, Freezing of Gait questionnaire, and levodopa equivalent dose), even when disease duration was taken into account. Conclusions. Abnormal olfaction in PD is associated with increased severity and faster disease progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据